Adverse effects of immunoglobulin G therapy: Thromboembolism and haemolysis

Clinical and Experimental Immunology

Volumn 178, Issue S1, 2014, Pages 72-74

  Bonilla, F A ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 11A; HAPTOGLOBIN; HEMOGLOBIN; IMMUNOGLOBULIN G; LACTATE DEHYDROGENASE;

ARTICLE; HEMOLYSIS; HUMAN; IMMUNOTHERAPY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RETICULOCYTE COUNT; THROMBOEMBOLISM; ADVERSE EFFECTS; IMMUNOLOGY; ODDS RATIO; PASSIVE IMMUNIZATION; PROCEDURES; RETROSPECTIVE STUDY;

HEMOLYSIS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; ODDS RATIO; RETROSPECTIVE STUDIES; THROMBOEMBOLISM;

EID: 84921494495     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12518     Document Type: Article

References (13)

1. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986; 2:217-218.
2. Daniel GW, Menis M, Sridhar G etal. Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. Transfusion 2012; 52:2113-2121.
3. Menis M, Sridhar G, Selvam N etal. Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008-2011. Am J Hematol 2013; 88:1035-1040.
4. Ovanesov MV. Laboratory investigations of products associated with thrombotic events. Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), 2011. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/UCM260788.pdf (accessed 10 December 2014).
5. Etscheid M, Breitner-Ruddock S, Gross S, Hunfeld A, Seitz R, Dodt J. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products. Vox Sang 2012; 102:40-46.
6. Turecek PL. Minimizing procoagulant impurities in IGIV products, Baxter's approach. Vienna, Austria: Baxter Bioscience; 2011. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/UCM260772.pdf (accessed 10 December 2014).
7. Rajabally YA, Kearney DA. Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study. J Neurol Sci 2011; 308:124-127.
8. Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013; 27:171-178.
9. Berard R, Whittemore B, Scuccimarri R. Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases. Pediatr Rheumatol Online J 2012; 10:10.
10. Health Canada. Intravenous immune globulin (IVIG): hemolytic reactions. CARN 2009; 19:1-3.
11. Desborough MJ, Miller J, Thorpe SJ, Murphy MF, Misbah SA. Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature. Transfus Med 2014; 24:219-226.
12. Bellac CL, Polatti D, Hottiger T, Girard P, Sanger M, Gilgen M. Anti-A and anti-B haemagglutinin levels in intravenous immunoglobulins: are they on the rise? A comparison of four different analysis methods and six products. Biologicals 2014; 42:57-64.
13. Siani B, Willimann K, Wymann S, Marques AA, Widmer E. Isoagglutinin reduction in human immunoglobulin products by donor screening. Biol Ther 2014; 4:15-26.